Home » EU Puts New Restrictions on the Use of Novartis’ Prexige
EU Puts New Restrictions on the Use of Novartis’ Prexige
In the wake of Australia’s decision to pull Novartis’ COX-2 inhibitor Prexige from the market, healthcare regulators in Europe and elsewhere are imposing restrictions on the drug over fears that it may cause serious liver damage.
PharmaTimes
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May